Inside USP: International Dialogue on Biologics Standards - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside USP: International Dialogue on Biologics Standards
USP promotes horizontal standards for biologics' quality attributes.

Pharmaceutical Technology
Volume 35, Issue 8, pp. 76-77

Hot topics

In deploying a horizontal approach to develop standards for biologics, USP's activities in the following areas are reflected in the themes of session tracks for the Science & Standards Symposium.

Bioassays. USP has developed a new suite of bioassay chapters that includes guidance and information focused on development, analysis and validation of biological assays. As a companion to these guidance chapters, USP has also developed example bioassay data sets and will make software analyses of the data available to meeting attendees. Case studies on analytical and compliance challenges related to bioassays as well as the assignment to biologics of quantities and values will be discussed.

Critical quality attributes for biologics. In the development of product-class standards, identification of critical quality attributes (CQAs) that apply across products within a designated class is key. USP <129> Critical Quality Attributes of Recombinant Therapeutic Monoclonal Antibodies is one example of a USP chapter in development which focuses on CQAs. In addition, USP <90> Fetal Bovine Serum—Quality Attributes and Functionality Tests became official in USP-NF in May 2011.

Ancillary materials and process enzymes. Ancillary materials, including growth factors and process enzymes, are necessary for the manufacture of certain biologics such as vaccines and cell-based or tissue-based therapies, but generally must be removed from the final product once the manufacturing process is complete. USP <1024> Bovine Serum addresses quality issues related to the production, sourcing, and characterization of this class of ancillary materials, with the intent of supporting its users in conducting risk assessment and implementing risk-mitigation measures.

Post-translational modifications. The functionality of a protein-based therapy is primarily based on its proper structure as well as correct post-translational modifications. USP General Chapter <1084> Glycoprotein and Glycan Analysis—General Considerations has been developed to address modifications that result from the process of glycosylation. In addition, USP currently is working on two chapters addressing compendial procedures for oligosaccharide and monosaccharide analysis, important for the manufacture of glycosylated proteins.

Analysis and regulation of bioassays. As technological improvements emerge, capabilities regarding bioassays must be updated to parallel those changes. Transitioning legacy products away from animal-based potency assays is an important issue for manufacturers. USP guidance chapters include <111> Design and Analysis of Biological Assays, which provides direction to users on developing appropriate strategies regarding biologic potency.

The topics of the conference speak broadly to industry professionals engaged in the development, analysis and quality control of biological medicines, as well as to professionals interested in the regulatory and compendial issues related to the latest trends in biotechnology. In support of its nearly 200-year-old mission to advance public health, USP is committed to continuing this global dialog among manufacturers, regulators, and practitioners to address the need for public quality standards for biologic medicines.

Register for the event

Tina Morris, PhD, is vice-president of biologics and biotechnology for the US Pharmacopeial Convention.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here